Reuters logo
8 months ago
BRIEF-Ab Initio Biotherapeutics announces strategic collaboration with Pfizer to discover GPCR activating antibodies
December 13, 2016 / 6:18 PM / 8 months ago

BRIEF-Ab Initio Biotherapeutics announces strategic collaboration with Pfizer to discover GPCR activating antibodies

Dec 13 (Reuters) - Ab Initio Biotherapeutics Inc:

* Ab Initio - addition of will somers, ph.d., vice president of biomedicines design at pfizer, to ab initio scientific advisory board

* Ab Initio - ab initio will receive an upfront fee and research support

* Ab Initio - co is eligible to receive milestone payments and tiered royalties on future sales of any products that may result from the collaboration

* Ab Initio -pfizer has exclusive worldwide rights to develop,commercialize gpcr activator antibodies against this target that may result from deal

* Ab Initio biotherapeutics - further terms of deal are not disclosed

* Ab Initio biotherapeutics - in addition, pfizer will make a strategic investment in ab initio alongside company's existing investors

* Ab Initio biotherapeutics - addition of will somers, vice president of biomedicines design at pfizer, to ab initio scientific advisory board

* Ab Initio announces strategic collaboration with pfizer to discover gpcr activating antibodies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below